We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Geron (GERN) Q3 Earnings: Will the Store Pull a Surprise?
Read MoreHide Full Article
Geron Corporation (GERN - Free Report) is scheduled to report third-quarter 2016 results on Nov 3 after the market closes.
In the last reported quarter, the company recorded a positive surprise of 28.57%. Let’s see how things are shaping up for the upcoming announcement.
Imetelstat Remains in Focus
With no approved product in its portfolio, Geron’s top line solely comprises license fees and royalties. In such a scenario, investor focus will remain on the company’s pipeline. Geron currently has one candidate in its pipeline, imetelstat, which is being developed in collaboration with Johnson & Johnson’s (JNJ - Free Report) Janssen Biotech.
The company’s shares took a hit this September when the company announced unfavorable findings from planned internal reviews of initial data from the two studies – IMbark (phase II) for the treatment of myelofibrosis, and IMerge (phase II/III) for the treatment of myelodysplastic syndromes.
Findings concluded that clinical activity of imetelstat in the 4.7 mg/kg dosing arm in the IMbark study did not warrant any further investigation and it will be closed to new patient enrollment. The company, however, is still evaluating imetelstat in the 9.4 mg/kg dosing arm, which was on hold. In the upcoming conference call, we expect the company to shed more light on the candidate.
In addition to updates on imetelstat, investors will also be interested to know if Geron has made any progress in expanding its pipeline. The company is seeking to add new oncology candidates, programs or companies to its portfolio with focus on the hematology-oncology space.
Like all development-stage companies, Geron too will to see a rise in research and development expenses.
Surprise History
Geron’s performance over the last four quarters has been mixed, with the company surpassing expectations twice and meeting the same twice. The average positive surprise over the last four quarters is 20.78%.
Our proven model does not conclusively show that Geron is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate Estimate and the current Zacks Consensus Estimate stand at a loss of 6 cents. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Zacks Rank: Although Geron’s Zacks Rank #1 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult this quarter.
Note that we caution against stocks with Zacks Ranks #4 or #5 (Sell-rated stocks) going into an earnings announcement, especially when the company is seeing a negative estimate revision momentum.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that they too have the right combination of elements to post an earnings beat this quarter.
Infinity Pharmaceuticals, Inc. is scheduled to release third-quarter results on Nov 3 after market closes. The company has an Earnings ESP of is +5.81% and it sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Earnings ESP for Zoetis Inc. (ZTS - Free Report) is +2.17% and it carries a Zacks Rank #3. The company is slated to release third-quarter results on Nov 2.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Geron (GERN) Q3 Earnings: Will the Store Pull a Surprise?
Geron Corporation (GERN - Free Report) is scheduled to report third-quarter 2016 results on Nov 3 after the market closes.
In the last reported quarter, the company recorded a positive surprise of 28.57%. Let’s see how things are shaping up for the upcoming announcement.
Imetelstat Remains in Focus
With no approved product in its portfolio, Geron’s top line solely comprises license fees and royalties. In such a scenario, investor focus will remain on the company’s pipeline. Geron currently has one candidate in its pipeline, imetelstat, which is being developed in collaboration with Johnson & Johnson’s (JNJ - Free Report) Janssen Biotech.
The company’s shares took a hit this September when the company announced unfavorable findings from planned internal reviews of initial data from the two studies – IMbark (phase II) for the treatment of myelofibrosis, and IMerge (phase II/III) for the treatment of myelodysplastic syndromes.
Findings concluded that clinical activity of imetelstat in the 4.7 mg/kg dosing arm in the IMbark study did not warrant any further investigation and it will be closed to new patient enrollment. The company, however, is still evaluating imetelstat in the 9.4 mg/kg dosing arm, which was on hold. In the upcoming conference call, we expect the company to shed more light on the candidate.
In addition to updates on imetelstat, investors will also be interested to know if Geron has made any progress in expanding its pipeline. The company is seeking to add new oncology candidates, programs or companies to its portfolio with focus on the hematology-oncology space.
Like all development-stage companies, Geron too will to see a rise in research and development expenses.
Surprise History
Geron’s performance over the last four quarters has been mixed, with the company surpassing expectations twice and meeting the same twice. The average positive surprise over the last four quarters is 20.78%.
GERON CORP Price and EPS Surprise
GERON CORP Price and EPS Surprise | GERON CORP Quote
What Our Model Indicates
Our proven model does not conclusively show that Geron is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate Estimate and the current Zacks Consensus Estimate stand at a loss of 6 cents. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Zacks Rank: Although Geron’s Zacks Rank #1 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult this quarter.
Note that we caution against stocks with Zacks Ranks #4 or #5 (Sell-rated stocks) going into an earnings announcement, especially when the company is seeing a negative estimate revision momentum.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that they too have the right combination of elements to post an earnings beat this quarter.
Infinity Pharmaceuticals, Inc. is scheduled to release third-quarter results on Nov 3 after market closes. The company has an Earnings ESP of is +5.81% and it sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Earnings ESP for Zoetis Inc. (ZTS - Free Report) is +2.17% and it carries a Zacks Rank #3. The company is slated to release third-quarter results on Nov 2.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>